Deals news from FierceBiotech
News
Elan wins $55M judgment in patent scrap
Ireland's Elan won a $55.2 million judgment against Abraxis BioScience on Friday, prevailing in its case that Abraxis' breast cancer drug Abraxane uses a technology protected by an Elan patent. Read more...
Report: Pfizer makes counter-offer for Ranbaxy
Pfizer may be crashing Daiichi Sankyo's party. Business Standard is reporting that Pfizer is considering a counter-offer for Ranbaxy, India's largest drugmaker. The rumor comes on the heels of the Read more...
Lilly pays $35M to land TransPharma pact
Eli Lilly is forking over a $35 million upfront payment to nail down the worldwide licensing rights to TransPharma Medical's ViaDerm-hPTH osteoporosis product and a non-exclusive license to its Read more...
Symphogen inks $330M collaboration pact with Genentech
Denmark's Symphogen has inked a $330 million collaboration deal with Genentech to discover new antibodies for three infectious disease Read more...
Novo Nordisk discontinues Phase III on disappointing results
Concluding that a late-stage trial of its experimental therapy to prevent bleeding in trauma patients was headed to a likely failure, Novo Nordisk discontinued the study of Read more...
Daiichi Sankyo acquires Ranbaxy in $4.6B deal
Ranbaxy's drive to become a research-based drug developer and major manufacturer has led it straight into the Read more...
Pfizer blazes new research path
Taking a page from the biotech playbook, Pfizer has just inked a three-year, $9.5 million research collaboration pact with the University of California, San Francisco. The money will be used to fund Read more...
Vertex shares rise on positive data for telaprevir
Vertex Pharmaceuticals saw a significant bump in its share price this morning after researchers released new, mid-stage interim data backing telaprevir for hepatitis C. The company is now penciling Read more...
Ipsen inks a string of deals in expansion effort
France's Ipsen is buying out Tercica in a $404 million deal, one of three new pacts designed to Read more...
Exelixis gets $150M credit line
Exelixis has struck a $150 million financing deal with Deerfield Management. At Exelixis discretion, the developer can draw down the money as needed over the next 18 months in $15 million Read more...
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets